ArticleJournal of cellular and molecular medicine2025
Daratumumab for CD20
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Multifunctional CD38 in the pathogenesis and treatment of B-cell lymphomas.American journal of blood research · 2026Review
- Anti-CD38 monoclonal antibodies in multiple myeloma and beyond: immunotherapeutic mechanisms, evidence maturity, and clinical positioning.Frontiers in immunology · 2026Review
- Daratumumab for CD20Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Patients with R/R DLBCL (relapsed/refractory diffuse large B-cell lymphoma) treated with rituximab-based regimens often have a reduction in the expression level of CD20. Replacement of target proteins for new targeted chemotherapy has become a popular direction for the treatment of R/R DLBCL. To investigate whether Daratumumab can be an effective alternative to targeted agents as monotherapy or combination chemotherapy in patients with CD20-CD38+ R/R DLBCL who have failed to respond to CD20 monoclonal antibody treatment and its adjuvant effect on subsequent CAR-T (chimeric antigen receptor T-cell immunotherapy). A total of four CD20-CD38+ R/R DLBCL patients treated with multiple lines of Daratumumab-based combination chemotherapy were retrospectively collected. For eligible patients, CAR-T therapy was used afterwards. Also, the authors successfully constructed allografted tumour models in mice. Relevant evaluation showed that four patients who received Daratumumab combination chemotherapy had varying degrees of remission after treatment, including 2 CR, 1 PR and 1 SD. The 1-year OS rate was 75%, the 1-year PFS rate was 50% and mOS was 12 months. Adverse effects were moderate and reversible, and no treatment-related deaths occurred. Daratumumab therapy led to a successful transition to CAR-T in two patients. Among them, grade 1 CRS occurred. These cases demonstrated that Daratumumab combination therapy has a good application prospect in the treatment of CD20-CD38+ R/R DLBCL and is helpful for the bridge of CAR-T therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.